Summit's ezutromid reduces muscle damage in DMD

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) reported interim 24-week data from the Phase II PhaseOut DMD trial showing that twice-daily ezutromid (SMT C1100) reduced muscle damage in Duchenne muscular dystrophy patients.

Compared to baseline, ezutromid significantly reduced muscle damage at week 24 by 23% as measured by mean developmental myosin. Of 22 evaluable patients, 14 showed a reduction in development myosin, which was greater than 40% in five patients...